Investors
Nov 16, 2026
Taipei, Taiwan, 16 November 2026 — Lotus Pharmaceutical (1795; “Lotus” or “the Company”), a global pharmaceutical company, today announced that its Chairman, Robert Wessman, has purchased 58,075 shares in the Company thr...

Investors
Nov 16, 2026
Taipei, Taiwan, 16 November 2026 — Lotus Pharmaceutical (1795; “Lotus” or “the Company”), a global pharmaceutical company, today announced that its Chairman, Robert Wessman, has purchased 58,075 shares in the Company thr...

Investors
Nov 12, 2026
Taipei, Taiwan, 12 Nov 2026 — Lotus Pharmaceutical (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced its financial results for the third quarter and first nine months ended 30 Septemb...

Investors
Nov 10, 2026
Taipei, Taiwan, 10 November 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for October 2026 of NT$2,135 million, repre...

Investors
Oct 12, 2026
Taipei, Taiwan, 12 October 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for September 2026 of NT$2,766 million, repr...

Business
Oct 7, 2026
Taipei, Taiwan, and Seoul, South Korea, 07 October 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced the completion of the acquisition of the South Kore...

Business
Sep 24, 2026
Taipei, Taiwan, 24 September 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing an Abbreviated N...



